Thyrocare Technologies Ltd Q4 FY25 Earnings Analysis

- Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% year-on-year consolidated revenue growth in Q3 driven by organic (19%) and inorganic (4%) growth. - Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY. - Vimta Labs acquisition is stabilizing; expected quarterly revenue from Vimta to be INR 3-4 crores for next 4 quarters before potential growth. - Expansion in insurance-related partnerships is ongoing, contributing about 10-13% of partnership revenues with expectation to deepen further. - Tanzania operations, still nascent, show potential with 100+ healthcare partners; revenue currently modest but expected to grow over time. - Q4 likely to continue momentum with a focus on sustaining mid to high-teen growth rates. - Strategy focuses on menu expansion, network deepening across India, and enhancing partner value to drive future volume and revenue growth.

- Thyrocare expects continued strong growth, with revenue growth much above the industry’s mid-teen growth rate, aiming to maintain the current high growth trajectory. - EBITDA margins are improving with a normalized consolidated EBITDA margin of around 30% and positive operating leverage. - Vimta acquisition currently shows an EBITDA loss (~INR 1.4 crore for the quarter), but losses are expected to reduce over the next 0.5 year toward zero. - ESOP non-cash charges impacting reported profits but expected to decline gradually after next few quarters as the vesting schedule progresses. - Depreciation includes a one-time INR 4.75 crore charge due to asset life revision; going forward, depreciation will stabilize. - Management optimistic about profit growth continuing despite recent margin pressures from acquisitions and increased expenses. - Overall, profit and EPS are expected to improve over the coming quarters as integrations stabilize and organic growth continues.

- Radiology Business: - No significant fresh capex planned; machines are old but still running. - Refurbished options will be considered only when machines reach end of life. - Overall Capex: - Up to Q3 FY25, about INR 15 crores spent. - Expected to spend another approximately INR 10 crores by year-end. - Capex primarily directed towards new labs and network expansion. - Strategic Investments: - Acquisitions of Polo Labs and Vimta Clinical Diagnostics to increase presence in North and South India. - Acquisition of Think Health to offer ECG at Home services, enhancing value to insurance partners. - ESOP Program: - New INR 47 crore pool created at API Holdings level to retain talent, with vesting over 5-6 years; non-cash expense impacting P&L but no cash outflow. Overall, capex focused on network and organic/inorganic growth, with conservative investment in radiology equipment.

- There is no mention of any current or planned fundraising through debt or equity in the provided transcript. - Rahul Guha explicitly confirms there is no dilution at Thyrocare, emphasizing the end of the Thyrocare ESOP program and clarifying that the increase in shares is due to vesting of ESOPs granted to employees, not fresh equity issuance. - The company has not discussed or contemplated any speculative reverse merger or related fundraising. - Capex plans are modest, with INR 25 crores estimated for FY '25 and no significant fresh capex planned for radiology; no need for large new funding rounds indicated. - The focus remains on organic growth, acquisitions, and improving margins without explicit plans for new equity or debt fundraisings.

The transcript provided does not mention any details about the current or expected order book or pending orders for Thyrocare Technologies Limited. The discussion primarily focuses on financial performance, acquisition updates (e.g., Vimta Labs), ESOP charges, pricing strategy, franchisee and partnership growth, and strategic direction. No specific information regarding order backlog or pending orders is disclosed in the available transcript.